DGX retail attention spikes to 3-sigma ahead of Q3

Retail attention on Quest Diagnostics has hit 3.2 standard deviations above its own 90-day average, per Wikipedia views and ORTEX stock page traffic, with Q3 results due Wednesday morning. That reading lands on top of an options market already positioned at its most bullish point in a year.

The crowd arrives late to a trade already in motion

The attention spike is confirmation of what options flow has been signalling for days. The put/call ratio closed Tuesday at 0.292, the lowest in 52 weeks and 2.4 standard deviations below the 20-day mean of 1.02. As recently as early October, the PCR sat above 1.37. It has collapsed in a straight line since, as call buyers overwhelmed protective put holders in the days immediately before the print.

Short interest has moved the same direction. Bears have cut positions by 12.1% over the past week. The float short now sits at 2.52%, the lowest since early September and down 22% over the past month. The lending market tells the same story. Availability stands at 1,799%, meaning roughly 18 shares are available to borrow for every one currently lent out. That is well above the 52-week low availability of 721%. There is no competition for borrows and no sign the lending pool is being drawn down in anticipation of new short positions.

Analysts lifted targets, the market trades below consensus

The analyst backdrop has been quietly constructive. Barclays raised its target to $260 on October 7, maintaining an Overweight. Truist and Mizuho both raised targets to $260 in September and July respectively. UBS moved to $245 in September. The mean price target across the coverage group stands at $251.73. The stock closed Tuesday at $237.12, leaving it roughly 6% below the consensus target.

Boston Partners was the most active institutional buyer as of the September 30 filing date, adding 732,241 shares in the quarter. BlackRock added 190,907 shares in the same period. No activist 13D filing is present on the register.

The analyst recommendation divergence factor sits at the 94th percentile, the highest-ranked factor score in the snapshot. That measures the gap between the current consensus and recent analyst movement direction. It points to a market still priced below where the most recent analyst actions are pointing.

What to watch

The Q3 print lands pre-market on October 22. The last quarterly release, in July, moved the stock 8.6% on the day and 11.7% over the following five trading sessions. The key metric to monitor is revenue per requisition: Barclays' bull case rests on advanced diagnostics demand holding firm, while the bear case centres on continued volume drag from Corewell and Fresenius and pricing pressure heading into 2026.

---

• PCR: 0.292, 52-week low, 2.4 standard deviations below 20-day mean
• Short interest: 2.52% of free float, down 12.1% in one week, down 22.1% in one month
• Availability: 1,799%, loosest since at least September; 52-week low was 721%
• Analyst mean target: $251.73 vs close of $237.12
• Retail attention: 3.2 standard deviations above 90-day average (Wikipedia views and ORTEX page traffic)
• Earnings: October 22, pre-market